Nuvaira develops a lung denervation system to treat obstructive lung diseases using a procedure called Targeted Lung Denervation (TLD). Its proprietary technology targets airway hyper-responsiveness, a pathophysiologic underpinning of COPD and asthma, and has demonstrated safety and feasibility in IPS-I/II, AIRFLOW-1, and the AIRFLOW-2 sham-controlled randomized trial. The Nuvaira Lung Denervation System is CE Mark approved and is under clinical investigation in the U.S.; it is not commercially available in the USA. The company will use the financing to support the pivotal AIRFLOW-3 clinical trial for FDA approval and to implement a targeted clinical development strategy in key European markets. Nuvaira closed a $79M equity financing to fund these efforts. The company is led by CEO Dennis Wahr, M.D., and recently added Lisa Rogan as senior vice president of market development. Holaira is a lung denervation company developing minimally invasive products to make breathing easier for patients suffering from obstructive lung diseases. The company is working on a novel catheter‑based system that has the potential to improve lung function, exercise capacity and quality of life for patients with chronic obstructive pulmonary disease. Founded in 2008 and led by president and chief executive officer Dennis Wahr, Holaira is based in Plymouth, MN. It recently raised $42M in Series D funding to advance its clinical program. The company intends to use the funds to support the first randomized lung denervation clinical trial with a sham control. In conjunction with the funding, Dr. Lincoln Chee of Vertex Venture Holdings joined Holaira’s board of directors. Holaira (fka Innovative Pulmonary Solutions) develops minimally invasive medical devices to treat obstructive lung diseases, including a novel catheter-based system for Targeted Lung Denervation aimed at easing breathing for COPD patients. The company is working to advance its minimally invasive product portfolio and intends to use the new capital to continue development. Holaira is led by president and CEO Dennis Wahr, M.D. and was founded in 2008. The company is based in Minneapolis, MN. Financially, Holaira completed a $10M Series C financing to support its product development efforts. Identified backers include Advanced Technology Ventures, Morgenthaler Ventures, Split Rock Partners and Versant Ventures.

Total raised

$131M

Funding rounds

3

Latest round

Equity

Latest activity

Feb 2019